Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]
, 2014 The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen +58 more
core +13 more sources
Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells : a randomised, double-blind placebo-controlled feasibility trial [PDF]
, 2020 Background: Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to sites of tissue injury.
Brighton, Paul (Paul J.) +13 more
core +1 more source
The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2020 Background: Dipeptidyl peptidase-4 (DPP4, DPPIV, CD26, EC 3.4.14.5) was found out more than four decades ago as a serine protease that severs N-terminal dipeptides from peptide substrates. DPP-4 inhibitors have been used in many animal models of lung and
Song-Chol Mun, Hye-Sun Hong
doaj +1 more source
Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
Molecules, 2022 In recent years, important changes have occurred in the field of diabetes treatment. The focus of the treatment of diabetic patients has shifted from the control of blood glucose itself to the overall management of risk factors, while adjusting blood ...
Ruili Yin +4 more
doaj +1 more source
Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis. [PDF]
Clin Mol HepatolChoi J +9 more
europepmc +2 more sources
Metabolism Open, 2021 COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 and has become an urgent economic and health challenge. Dipeptidyl peptidase 4 (DPP4), also mentioned as a cluster of differentiation 26 (CD26) is a serine exopeptidase found in two ...
Zemene Demelash Kifle +2 more
doaj +1 more source
Dipeptidyl peptidase 4 inhibitors in modern domestic practice
Медицинский совет, 2020 The choice of treatment of diabetes mellitus type 2 is personalized, based on modern Russian and international algorithms for management of such patients.
A. S. Ametov +2 more
doaj +1 more source
DPP4 (dipeptidyl-peptidase 4) [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2013 Review on DPP4 (dipeptidyl-peptidase 4), with data on DNA, on the protein encoded, and where the gene is implicated.
Ohnuma, K, Morimoto, C
openaire +2 more sources
Solvent and thermal stability, and pH kinetics, of proline-specific dipeptidyl peptidase IV-like enzyme from bovine serum [PDF]
, 2007 Proline-specific dipeptidyl peptidase-like (DPP IV; EC 3.4.14.5) activity in bovine serum has attracted little attention despite its ready availability and the paucity of useful proline-cleaving enzymes.
Abbott +43 more
core +1 more source
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors [PDF]
Diabetes & Metabolism Journal, 2022 Background It is not known which type 2 diabetes mellitus (T2DM) patients would most benefit from dipeptidyl peptidase-4 (DPP-4) inhibitor treatment.
Sangmo Hong +3 more
doaj +1 more source